What is Viking Therapeutics?
Founded in 2012, Viking Therapeutics is a clinical-stage biopharmaceutical firm dedicated to pioneering novel, orally administered treatments for metabolic and endocrine disorders. The company's core focus lies in the research and development of innovative therapeutics designed to enhance patient outcomes through metabolic targeting. Viking Therapeutics boasts a diverse portfolio of clinical programs, including potential treatments for lipid and metabolic disorders, X-linked adrenoleukodystrophy, and recovery support for patients post-hip fracture. Additionally, the company is advancing earlier-stage initiatives aimed at addressing various metabolic diseases and anemia. Viking Therapeutics operates under exclusive worldwide rights for a suite of small molecule therapeutic programs licensed from other pharmaceutical entities, positioning it as a key player in the development of next-generation metabolic and endocrine therapies.
How much funding has Viking Therapeutics raised?
Viking Therapeutics has raised a total of $24M across 1 funding round:
Stock Offering
$24M
Stock Issuance/Offering (2015): $24M, investors not publicly disclosed
What's next for Viking Therapeutics?
The recent major strategic investment signifies a pivotal moment for Viking Therapeutics, likely enabling the acceleration of its clinical development programs and the expansion of its research initiatives. This capital infusion is expected to fuel the progression of its pipeline candidates through crucial clinical trial phases, potentially bringing novel therapies for metabolic and endocrine disorders closer to market. The company's focus on orally available treatments addresses a significant unmet need, and this funding will be instrumental in solidifying its market position and advancing its mission to improve patient care through innovative pharmaceutical solutions. Strategic partnerships and further research endeavors are anticipated as Viking Therapeutics leverages this financial backing to drive innovation and growth.
See full Viking Therapeutics company page
